Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GSK Opens Rare Diseases Medicine Development Center in Japan
April 26, 2010
- Kenko.com Appeals Aiming at Online Sale of Classes 1, 2 OTC Drugs
April 26, 2010
- Shionogi's Demand Rejected in Flomox Patent Litigation
April 26, 2010
- Kenporen Members to Report Record-High Deficit of ¥660 Bil.
April 26, 2010
- BI Launches Global Venture Fund
April 26, 2010
- Isentress Recommended for Lack of Effects on Lipids: Dr Hanabusa
April 26, 2010
- Biomedical Cluster Kansai Changes Its Operation Systems
April 26, 2010
- Only 12.6% of the Elderly Aware of Pneumococcal Vaccines
April 26, 2010
- 14 New Products Approved by Korosho
April 26, 2010
- 3,787 Pass National Exam for Pharmacists with Pass Rate of 56.35%
April 26, 2010
- FPMAJ to Determine Measures to Enhance Ethical Compliance
April 26, 2010
- Bayer to Increase Sales of New Drugs to 50% of Total Sales
April 26, 2010
- Extended Survival Most Wanted by Breast Cancer Patients: Survey
April 26, 2010
- Korosho Calls For Enhancement of Compliance
April 26, 2010
- MSD to Boost Sales to ¥500 Bil. Within 5 Years
April 26, 2010
- Mr Mitani Proposes Review of PMDA's NDA Review System
April 26, 2010
- US Pharm. Market Up 5.1% to US$300 Bil. in 2009: IMS Health
April 26, 2010
- 23% of Pharmacies Aim at Generic Usage Rate of Over 30%
April 26, 2010
- MTPC Ordered to Suspend Business for 25 Days
April 26, 2010
- Taiyo Puts End to “One-Stop Generic Company”Policy
April 26, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…